First trimester screening for Down syndrome using nuchal translucency, maternal serum pregnancy‐associated plasma protein A, free‐β human chorionic gonadotrophin, placental growth factor, and α‐fetoprotein

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 7, 2015-07 ,pp. : 709-716

John Wiley & Sons Inc

Access to resources Recommend Favorite

Diagnostic value of ultrasonographic combining biochemical markers for Down syndrome screening in first trimester: a meta‐analysis

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 9, 2015-09 ,pp. : 879-887

John Wiley & Sons Inc

Access to resources Recommend Favorite

Impact of a shift in nuchal translucency measurements on the detection rate of first‐trimester Down syndrome screening: A population‐based study

By  

PRENATAL DIAGNOSIS, Vol. 38, Iss. 2, 2018-01 ,pp. : 106-109

John Wiley & Sons Inc

Access to resources Recommend Favorite

First trimester Down syndrome screening: Distribution of markers and comparison of assays for quantification of pregnancy‐associated plasma protein‐A

By Wøjdemann K. R.   Larsen S. O.   Rode L.   Shalmi A.   Sundberg K.   Christiansen M.   Tabor A.  

Scandinavian Journal of Clinical and Laboratory Investigation, Vol. 66, Iss. 2, 2006-04 ,pp. : 101-112

Informa Healthcare

Access to resources Recommend Favorite

Evaluating first trimester maternal serum screening combinations for Down syndrome suitable for use with reflexive secondary screening via sequencing of cell free DNA: high detection with low rates of invasive procedures

By  

PRENATAL DIAGNOSIS, Vol. 35, Iss. 8, 2015-08 ,pp. : 789-796

John Wiley & Sons Inc

Access to resources Recommend Favorite